ESMO 2019 | NIVOREN GETUG-AFU 26: Updates and implications

Laurence Albiges

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, speaking on the NIVOREN GETUG-AFU 26 study: the real-world implications of nivolumab in metastatic renal cell carcinoma patients. This interview was recorded at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter